Perjeta® | Pertuzumab | Roche

February 18, 2019

15 Feb 2019 | UK | Roche | In its final appraisal of pertuzumab, the National Institute for Health and Care Excellence (NICE) has recommended it for the treatment of lympth node-positive disease. The final appraisal comes following the promise of a large discount offered by Roche.

 

17 Dec 2018 | All | NeuClone | NeuClone announces that it has biosimilar pertuzumab in preclinical development.

 

20 Aug 2018 | UK | Roche  | The National Institute for Health and Care Excellence  (NICE) again recommends against Roche's application for pertuzumab as an adjuvant treatment in patients with a high risk of recurrence. NICE confirmed its earlier findings that pertuzumab is unlikely to be cost-effective, with clinical trials revealing only a small incremental treatment benefit.

 

15 Jun 2018 | UK | Roche | The National Institute for Health and Care Excellence (NICE) rejects pertuzumab for adjuvant treatment of early breast cancer. The draft guidance reports that the drug may not extend patient's lives and is not cost effective.

 

26 Apr 2018 | All | Mylan/Biocon | Biocon announces Biocon and Mylan add insulin glargine 300 and pertuzumab to their collaboration. 

 

 

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

November 9, 2020

Please reload

Search by tags